0000950170-23-035679.txt : 20230731
0000950170-23-035679.hdr.sgml : 20230731
20230731075844
ACCESSION NUMBER: 0000950170-23-035679
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230727
FILED AS OF DATE: 20230731
DATE AS OF CHANGE: 20230731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Parker Geoffrey M.
CENTRAL INDEX KEY: 0001491874
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39864
FILM NUMBER: 231125063
MAIL ADDRESS:
STREET 1: 15 RIORDAN PLACE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Better Therapeutics, Inc.
CENTRAL INDEX KEY: 0001832415
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 548 MARKET ST. #49404
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94101
BUSINESS PHONE: 415-887-2311
MAIL ADDRESS:
STREET 1: 548 MARKET ST. #49404
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94101
FORMER COMPANY:
FORMER CONFORMED NAME: Mountain Crest Acquisition Corp II
DATE OF NAME CHANGE: 20201116
4
1
ownership.xml
4
X0508
4
2023-07-27
0001832415
Better Therapeutics, Inc.
BTTX
0001491874
Parker Geoffrey M.
C/O BETTER THERAPEUTICS, INC.
548 MARKET STREET, #49404
SAN FRANCISCO
CA
94104
true
false
false
false
false
Common Stock
2023-07-27
4
P
false
685025
0.7299
A
1028055
D
Common Stock
53333
I
By Parker Trust
On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share.
As one of the PIPE Investors, the Reporting Person acquired 685,025 shares of Issuer common stock on July 27, 2023 for $0.7299 per share.
These shares are owned directly by the Geoffrey M. Parker and Jill G. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust.
/s/ Mark Heinen, Attorney-in-Fact
2023-07-31